TCDA · Tricida, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $19.93M | $16.86M | $18.50M | - | $26.64M | $19.78M | $32.17M | - | $43.00M | $28.76M |
| SG&A | $4.13M | $9.82M | $9.17M | - | $9.05M | $9.55M | $9.89M | - | $29.27M | $28.42M |
| Total Operating Expenses | $24.06M | $26.68M | $27.67M | - | $35.69M | $29.33M | $42.07M | - | $72.27M | $57.17M |
| D&A | - | - | $81.0K | - | - | - | $134.0K | - | $200.0K | $200.0K |
| Operating Income | ($24.06M) | ($26.68M) | ($27.67M) | - | ($35.69M) | ($29.33M) | ($42.07M) | - | ($72.27M) | ($57.17M) |
| Interest Expense | $1.98M | $1.98M | $1.97M | - | $3.99M | $3.93M | $5.61M | - | $6.27M | $3.76M |
| Income Tax | - | - | - | - | $0 | $0 | - | - | $36.0K | ($86.0K) |
| Net Income | ($25.76M) | ($28.54M) | ($29.64M) | - | ($39.67M) | ($33.55M) | ($53.36M) | - | ($77.67M) | ($58.17M) |
| EPS - Basic | ($0.44) | ($0.49) | ($0.51) | - | ($1.55) | ($1.16) | ($1.49) | - | - | - |
| EPS - Diluted | ($0.44) | ($0.49) | ($0.51) | - | ($0.79) | ($0.67) | ($1.49) | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.74M | $22.15M | $17.71M | $21.11M | $16.99M | $22.86M | $40.51M | $137.86M | $29.71M | $41.90M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.39M | $3.74M | $5.54M | $10.02M | $3.26M | $2.74M | $5.32M | $3.51M | $1.79M | $5.84M |
| Current Assets | $82.48M | $102.38M | $128.00M | $145.54M | $151.17M | $181.03M | $220.72M | $314.01M | $326.06M | $397.36M |
| Total Assets | $93.88M | $114.29M | $140.41M | $168.51M | $164.59M | $194.95M | $235.17M | $351.69M | $399.67M | $456.90M |
| Current Liabilities | $16.93M | $20.05M | $24.99M | $29.48M | $25.73M | $24.87M | $40.20M | $34.26M | $46.58M | $34.48M |
| Long-term Debt | - | - | - | $0 | $0 | $0 | $0 | $76.64M | $61.96M | $67.95M |
| Total Liabilities | $229.98M | $225.51M | $230.71M | $168.29M | $162.68M | $160.02M | $173.61M | $242.81M | $238.90M | $225.92M |
| Stockholders' Equity | ($136.10M) | ($111.22M) | ($90.30M) | $218.0K | $1.90M | $34.93M | $61.56M | $108.87M | $160.77M | $230.98M |
| Retained Earnings | ($881.96M) | ($856.20M) | ($827.66M) | ($810.36M) | ($760.39M) | ($720.71M) | ($687.16M) | ($633.80M) | ($578.96M) | ($501.29M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($26.40M) | - | - | - | ($30.98M) | - | - | - |
| Investing Cash Flow | - | - | $23.19M | - | - | - | $16.82M | - | - | - |
| Financing Cash Flow | - | - | ($190.0K) | - | - | - | ($83.19M) | - | - | - |
| CapEx | - | - | $0 | - | - | - | $76.0K | - | - | - |
| Free Cash Flow | - | - | ($26.40M) | - | - | - | ($31.05M) | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.89 | - | - | - | 0.58 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -27.4% | -25.0% | -21.1% | - | -24.1% | -17.2% | -22.7% | - | -19.4% | -12.7% |
| Return on equity | 18.9% | 25.7% | 32.8% | - | -2086.0% | -96.1% | -86.7% | - | -48.3% | -25.2% |
| Return on invested capital | - | - | - | - | -1482.3% | -66.3% | - | - | -25.6% | -15.1% |
| Liquidity | ||||||||||
| Current ratio | 4.87 | 5.11 | 5.12 | 4.94 | 5.88 | 7.28 | 5.49 | 9.17 | 7.00 | 11.52 |
| Quick ratio | 4.87 | 5.11 | 5.12 | 4.94 | 5.88 | 7.28 | 5.49 | 9.17 | 7.00 | 11.52 |
| Cash ratio | 1.05 | 1.11 | 0.71 | 0.72 | 0.66 | 0.92 | 1.01 | 4.02 | 0.64 | 1.22 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.70 | 0.39 | 0.29 |
| Debt / Assets | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.16 | 0.15 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -12.2x | -13.5x | -14.0x | - | -8.9x | -7.5x | -7.5x | - | -11.5x | -15.2x |
| Equity multiplier | -0.69 | -1.03 | -1.55 | 772.96 | 86.53 | 5.58 | 3.82 | 3.23 | 2.49 | 1.98 |
| Liabilities / Assets | 2.45 | 1.97 | 1.64 | 1.00 | 0.99 | 0.82 | 0.74 | 0.69 | 0.60 | 0.49 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 32.6% | 9.0% | 34.2% | - | 50.6% | 48.7% | 42.3% | - | -60.3% | -51.1% |
| Net income growth (YoY) | 35.1% | 15.0% | 44.5% | - | 48.9% | 42.3% | 28.0% | - | -76.0% | -58.8% |
| EPS growth (YoY) | 44.3% | 26.9% | 65.8% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 15.0% | - | - | - | 39.6% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -99.8% | -98.8% | -84.9% | -69.0% | -58.7% | -48.4% | -33.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Tricida against the 5 most active filers in the same SIC group.